Harbin

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Lung cancer3 trials
• Metastatic breast cancer3 trials
• Stroke3 trials
• Familial hypercholesterolaemia2 trials
• Macular degeneration2 trials
• Ankylosing spondylitis1 trial
• Gastric and oesophageal cancer1 trial
• Multiple sclerosis1 trial

Phase

• Phase 38 trials
• Phase 25 trials
• Phase 42 trials

Status

• Completed9 trials
• Active, not recruiting5 trials
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals15 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Roll-over Study to Allow Continued Access to Ribociclib

  NCT05161195· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

  NCT04544189· Phase 2· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

  NCT05199571· Phase 4· Novartis Pharmaceuticals· Source

• Terminated

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

  NCT05230537· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

  NCT04732117· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

  NCT04677595· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

  NCT04452877· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

  NCT04047472· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

  NCT03671330· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

  NCT00680901· Phase 3· Novartis Pharmaceuticals· Source